References

nnp

Neurology, Neuropsychiatry, Psychosomatics

Неврология, нейропсихиатрия, психосоматика

2074-27112310-1342

"IMA-Press", LLC

10.14412/2074-2711-2018-3-129-134

nnp-961

Research Article

REVIEWS

ОБЗОРЫ

Alzheimer's disease: some pharmacological and non-pharmacological approaches to correcting neuropsychiatric disorders

Болезнь Альцгеймера: фармакологические и нефармакологические подходы к коррекции психоневрологических расстройств

Менделевич

Е. Г.

Mendelevich

E. G.

Кафедра неврологии и реабилитации

Department of Neurology and Rehabilitation

emendel@mail.ru

ФГБОУ ВО «Казанский государственный медицинский университет», Казань, Республика ТатарстанРоссияKazan State Medical University, Kazan, Republic of Tatarstan, Russia 49, Butlerov St., Kazan, Republic of TatarstanRussian Federation

2018

09112018

103129134

2018

Менделевич Е.Г.

Mendelevich E.G.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://nnp.ima-press.net/nnp/article/view/961

Today, there is no reliable pharmacological correction of dementia, despite its high prevalence worldwide. The clinical presentation of Alzheimer's disease at one or another stage is accompanied by neuropsychiatric disorders (NPDs) in addition to cognitive defect. The intensity and range of NPDs are different. The possibilities of drug therapy for NPDs are demonstrated. The role of akatinol memantine in correcting a number of psychological and behavioral disorders is highlighted. Biological, psychological, social, and environmental factors are identified among those that contribute to or provoke the development of NPDs. Knowledge of the triggers of mental disorders makes it possible to prevent and thereby reduce or eliminate NPDs. Special emphasis is laid on the patient-caregiver relationship. In recent years, non-pharmacological interventions have been increasingly used as priority-line therapy for NPDs. There are data on main methods for non-pharmacological correction and on the efficiency of their application.

Сегодня отсутствует надежная фармакологическая коррекция деменции, несмотря на ее высокую распространенность во всем мире. Клиническая картина болезни Альцгеймера (БА) на той или иной стадии сопровождается присоединением к когнитивному дефекту нейропсихических нарушений (НПН). Выраженность и спектр НПН различны. Продемонстрированы возможности лекарственной терапии при НПН. Отмечена роль акатинола мемантина в коррекции ряда психолого-поведенческих расстройств. Среди факторов, способствующих формированию НПН или провоцирующих их, выделяют биологические, психологические, социальные и экологические. Знание триггеров психических расстройств позволяет избегать и тем самым уменьшить или устранить НПН. Особое внимание уделяется взаимоотношениям больного и ухаживающего лица. В последние годы в лечении НПН все чаще используются нефармакологические средства, считающиеся приоритетной линией их коррекции. Приводятся данные об основных методах нефармакологической коррекции и эффективности их применения.

болезнь Альцгеймерадеменциянейропсихические нарушенияфармакологическая и нефармакологическая коррекцияакатинол мемантин

Alzheimer's diseasedementianeuropsychiatric disorderspharmacological and non-pharmacological correctionakatinol memantine

References1

Яхно НН, Захаров ВВ, Локшина АБ и др. Деменции: руководство для врачей. Москва: МЕДпреcс-информ; 2011. 272 с. [Yakhno NN, Zakharov VV, Lokshina AB, et al. Dementsii: rukovodstvo dlya vracheii [Dementia: a guide for doctors]. Moscow: MEDpress-inform; 2011. 272 p.].

Парфенов ВА, Захаров ВВ, Преображенская ИС. Когнитивные расстройства. Москва: Ремедиум; 2014. 192 с. [Parfenov VA, Zakharov VV, Preobrazhenskaya IS. Kognitivnye rasstroistva [Cognitive impairments]. Moscow: Remedium; 2014. 192 p.].

De la Torre J. The Vascular Hypothesis of Alzheimer's Disease: A Key to Preclinical Prediction of Dementia Using Neuroimaging. J Alzheimers Dis. 2018;63(1):35-52. doi: 10.3233/JAD-180004.

Weinstein J. A new direction for Alzheimer's research. Neural Regen Res. 2018 Feb; 13(2):190-193. doi: 10.4103/1673-5374.226381.

Парфенов ВА, Кабаева АР. Ведение пациентов с болезнью Альцгеймера. Медицинский совет. 2018;(1):6-12. [Parfenov VA, Kabaeva AR. Management of patients with Alzheimer's disease. Meditsinskii sovet. 2018; (1):6-12. (In Russ.)].

Kales H, Gitlin L, Lyketsos C. Nonpharmacologic management of behavioral symptoms in dementia. JAMA. 2012 Nov 21;308(19): 2020-9. doi: 10.1001/jama.2012.36918.

Ijaopo E. Dementia-related agitation: a review of non-pharmacological interventions and analysis of risks and benefits of pharmacotherapy. Transl Psychiatry. 2017 Oct 31; 7(10):e1250. doi: 10.1038/tp.2017.199.

Lyketsos C, Carrillo M, Ryan J, et al. Neuropsychiatric symptoms in Alzheimer’s disease. Alzheimers Dement. 2011 Sep;7(5):532-9. doi: 10.1016/j.jalz.2011.05.2410.

Monastero R, Mangialasche F, Camarda C, et al. A systematic review of neuropsychiatric symptoms in mild cognitive impairment. J Alzheimers Dis. 2009;18(1):11-30. doi: 10.3233/JAD-2009-1120.

Менделевич ЕГ. Когнитивные и некогнитивные нейропсихические расстройства при деменции и методы их коррекции. Неврология, нейропсихиатрия, психосоматика. 2017;9(2):65–70. [Mendelevich EG. Cognitive and non-cognitive neuropsychiatric disorders in dementia and methods of their correction. Nevrologiya, nei?ropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2017;9(2):65–70. (In Russ.)]. doi: 10.14412/ 2074-2711-2017-2-65-70

Benoit M, Staccini P, Brocker P, et al. Behavioral and psychologic symptoms in Alzheimer’s disease: results of the REAL. FR study. Rev Med Interne. 2003 Oct;24 Suppl 3: 319s-324s.

Cerejeira J, Lagarto L, Mukaetova-Ladinska E. Behavioral and Psychological Symptoms of Dementia. Front Neurol. 2012 May 7;3:73. doi: 10.3389/fneur.2012.00073. eCollection 2012.

Steinberg M, Shao H, Zandi P, et al; Cache County Investigators. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: The Cache County study. Int J Geriatr Psychiatry. 2008 Feb;23(2):170-7.

Acharya D, Harper D, Achtyes E, et al. Safety and utility of acute electroconvulsive therapy for agitation and aggression in dementia. Int J Geriatr Psychiatry. 2015 Mar;30(3): 265-73. doi: 10.1002/gps.4137. Epub 2014 May 16.

Cohen-Mansfield J, Marx M, Dakheel-Ali M, et al. Can agitated behavior of nursing home residents with dementia be prevented with the use of standardized stimuli? J Am Geriatr Soc. 2010 Aug;58(8):1459-64. doi: 10.1111/j.1532-5415.2010.02951.x. Epub 2010 Jun 23.

Masopust J, Protopopova D, Valis M, et al. Treatment of behavioral and psychological symptoms of dementias with psychopharmaceuticals: a review. Neuropsychiatr Dis Treat. 2018 May 9;14:1211-1220. doi: 10.2147/ NDT.S163842. eCollection 2018.

Spector A, Orrell M, Goyder J. A systematic review of staff training interventions to reduce the behavioural and psy- chological symptoms of dementia. Ageing Res Rev. 2013 Jan;12(1): 354-64. doi: 10.1016/j.arr.2012.06.005. Epub 2012 Jul 20.

Algase D, Beck C, Kolanowski A, et al. Need-driven dementia-compromised behavior: An alternative view of disruptive behavior. American Journal of Alzheimer’s Disease and Other Dementias. 1996 Jan;11(6):10–9.

doi: 10.1177/153331759601100603

Cohen-Mansfield J, Dakheel-Ali M, Marx M, et al. Which unmet needs contribute to behavior problems in persons with advanced dementia? Psychiatry Res. 2015 Jul 30;228(1): 59-64. doi: 10.1016/j.psychres.2015.03.043. Epub 2015 Apr 14.

Hall, G, Buckwalter K. Progressively lowered stress threshold: A conceptual model for care of adults with Alzheimer’s disease. Arch Psychiatr Nurs. 1987 Dec;1(6):399-406.

Walker V, Davies N, Kehoe P, et al. What is the impact of regulatory guidance and expiry of drug patents on dementia drug prescriptions in England? A trend analysis in the Clinical Practice Research Datalink. Alzheimers Res Ther. 2018 May 29;10(1):51. doi: 10.1186/ s13195-018-0379-6.

Гаврилова СИ. Мемантин в лечении болезни Альцгеймера: 20 лет клинического применения. Журнал неврологии и психиатрии им. С.С. Корсакова. 2016;116(6):10-8. [Gavrilova SI. Memantine in the treatment of Alzheimer's disease: 20 years of clinical use. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2016;116(6):10-8. (In Russ.)].

Tanqueiro S, Ramalho R, Rodrigues M, et al. Inhibition of NMDA Receptors Prevents the Loss of BDNF Function Induced by Amyloid . Front Pharmacol. 2018 Apr 11;9:237. doi: 10.3389/fphar.2018.00237. eCollection 2018.

McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD003154.

Tsoi K, Chan J. Monotherapy Is Good Enough for Patients with Mild-to-Moderate Alzheimer's Disease: A Network Meta-analysis of 76 Randomized Controlled Trials. Clin Pharmacol Ther. 2018 May 1. doi: 10.1002/ cpt.1104. [Epub ahead of print].

Chen R, Chan P, Chu H, et al. Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: A meta-analysis. PLoS One. 2017 Aug 21;12(8):e0183586. doi: 10.1371/journal. pone.0183586. eCollection 2017.

Taylor D, Paton C, Kapur S. Prescribing Guidelines in Psychiatry. 12th ed. UK: John Wiley & Sons; 2015. 760 p.

Staedtler A, Nunez D. Nonpharmacological therapy for the management of neuropsychiatric symptoms of Alzheimer’s disease: Linking evidence to practice. Worldviews Evid Based Nurs. 2015 Apr;12(2):108-15. doi: 10.1111/wvn.12086. Epub 2015 Mar 21.

Sink K, Holden K, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: A review of the evidence. JAMA. 2005 Feb 2;293(5):596-608.

Panza F, Solfrizzi V, Seripa D, et al. Progresses in treating agitation: a major clinical challenge in Alzheimer’s disease. Expert Opin Pharmacother. 2015;16(17):2581-8. doi: 10.1517/14656566.2015.1092520. Epub 2015 Sep 21.

Scales K, Zimmerman S, Miller S. Evidence-Based Nonpharmacological Practices to Address Behavioral and Psychological Symptoms of Dementia. Gerontologist. 2018 Jan 18;58(suppl_1):S88-S102. doi: 10.1093/geront/gnx167.

Fazio S, Pace D, Flinner J, et al. The fundamentals of person-centered care for individuals with dementia. Gerontologist. 2018 Jan 18;58(suppl_1):S10-S19. doi: 10.1093/geront/ gnx122.

Molinari V, Chiriboga D, Branch L, et al. Provision of psychopharmacological services in nursing homes. J Gerontol B Psychol Sci Soc Sci. 2010 Jan;65B(1):57-60. doi: 10.1093/geronb/ gbp080. Epub 2009 Oct 21.

Cohen-Mansfield J, Juravel-Jaffe A, Cohen A, et al. Physicians' practice and familiarity with treatment for agitation associated with dementia in Israeli nursing homes. Int Psychogeriatr. 2013 Feb;25(2):236-44.

doi: 10.1017/S104161021200172X. Epub 2012 Oct 30.

Austrom M, Boustani M, LaMantia M. Ongoing Medical Management to Maximize Health and Well-being for Persons Living With Dementia. (Practice Recommendations for Medical Management). Gerontologist. 2018 Jan 18;58(suppl_1):S48-S57. doi: 10.1093/geront/ gnx147.

Millan-Calenti J, Lorenzo-Lopez L, Alonso-Bua B, et al. Optimal nonpharmacological management of agitation in Alzheimer’s disease: challenges and solutions. Clin Interv Aging. 2016 Feb 22;11:175-84. doi: 10.2147/ CIA.S69484. eCollection 2016.

Behrman S, Chouliaras L, Ebmeier K. Considering the senses in the diagnosis and management of dementia. Maturitas. 2014 Apr; 77(4):305-10. doi: 10.1016/j.maturitas.2014.01.003. Epub 2014 Jan 18.

Strom B, Ytrehus S, Grov E. Sensory stimulation for persons with dementia: A review of the literature. J Clin Nurs. 2016 Jul;25(13-14): 1805-34. doi: 10.1111/jocn.13169. Epub 2016 Mar 31.

Livingston G, Kelly L, Lewis-Holmes E, et al. Non- pharmacological interventions for agitation in dementia: systematic review of randomised controlled trials. Br J Psychiatry. 2014 Dec;205(6):436-42. doi: 10.1192/bjp.bp.113. 141119.

O'Connor D, Eppingstall B, Taffe J, et al. A randomized, controlled cross-over trial of dermally-applied lavender (Lavandula angustifolia) oil as a treatment of agitated behaviour in dementia. BMC Complement Altern Med. 2013 Nov 13;13:315. doi: 10.1186/1472-6882-13-315.

Hansen N, Jorgensen T, Ortenblad L. Massage and touch for dementia. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD004989.

Randall E, Clissett P. What are the relative merits of interventions used to reduce the occurrences of disrup- tive vocalisation in persons with dementia? A systematic review. Int J Older People Nurs. 2016 Mar;11(1):4-17.

doi: 10.1111/opn.12083. Epub 2015 Jun 29.

Sanchez A, Millan-Calenti J, Lorenzo-Lopez L, et al. Multisensory stimulation for people with dementia: A review of the literature. Am J Alzheimers Dis Other Demen. 2013 Feb;28(1):7-14. doi: 10.1177/1533317512466693. Epub 2012 Dec 7.

Cabrera E, Sutcliffe C, Verbeek H, et al; RightTimePlaceCare Consortium. Nonpharmacological interventions as a best practice strategy in people with dementia living in nursing homes: A systematic review. European Geriatric Medicine. 2015;(6):134–50.

Testad I, Corbett A, Aarsland D, et al. The value of personalized psychosocial interventions to address behavioral and psychological symptoms in people with dementia living in care home settings: A systematic review. Int Psychogeriatr. 2014 Jul;26(7):1083-98. doi: 10.1017/S1041610214000131. Epub 2014 Feb 24.

Cammisuli D, Danti S, Bosinelli F, et al. Non-pharmacological interventions for people with Alzheimer’s disease: A critical review of the scientific literature from the last ten years. European Geriatric Medicine. 2016;(7):57–64.

Chang Y, Chu H, Yang C. The ef cacy of music therapy for people with dementia: A meta-analysis of randomised controlled trials. J Clin Nurs. 2015 Dec;24(23-24):3425-40. doi: 10.1111/jocn.12976. Epub 2015 Aug 24.

Sakamoto M, Ando H, Tsutou A. Comparing the effects of different individualized music interventions for elderly individuals with severe dementia. Int Psychogeriatr. 2013 May; 25(5):775-84. doi: 10.1017/S1041610212002256. Epub 2013 Jan 8.

Abraha I, Rimland J, Trotta F, et al. Systematic review of systematic reviews of nonpharmacological interventions to treat behavioural disturbances in older patients with dementia. The SENATOR- OnTop series. BMJ Open. 2017 Mar 16;7(3):e012759. doi: 10.1136/ bmjopen-2016-012759.

The authors declare that there are no conflicts of interest present.